GSA Capital Partners LLP purchased a new position in Core Laboratories (NYSE:CLB) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 17,974 shares of the oil and gas company’s stock, valued at approximately $274,000.

A number of other hedge funds have also made changes to their positions in CLB. Marshall Wace LLP purchased a new stake in Core Laboratories in the first quarter worth $30,000. FMR LLC lifted its position in Core Laboratories by 173.3% during the first quarter. FMR LLC now owns 40,935 shares of the oil and gas company’s stock valued at $2,821,000 after buying an additional 25,955 shares during the period. Advisor Group Holdings Inc. purchased a new position in Core Laboratories during the first quarter valued at $32,000. Morgan Stanley lifted its position in Core Laboratories by 137.3% during the first quarter. Morgan Stanley now owns 876,426 shares of the oil and gas company’s stock valued at $9,062,000 after buying an additional 507,141 shares during the period. Finally, State Street Corp lifted its position in Core Laboratories by 9.4% during the first quarter. State Street Corp now owns 825,685 shares of the oil and gas company’s stock valued at $8,569,000 after buying an additional 71,029 shares during the period. 90.39% of the stock is owned by institutional investors.

Several equities analysts have commented on the company. Smith Barney Citigroup lowered their price objective on Core Laboratories from $21.00 to $16.00 in a research report on Friday, October 23rd. Morgan Stanley raised Core Laboratories from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, November 10th. ABN Amro raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Tuesday, September 29th. Cowen reduced their price target on Core Laboratories from $26.00 to $20.00 and set a “market perform” rating for the company in a report on Wednesday, November 11th. Finally, ValuEngine upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, November 10th. Twelve analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Core Laboratories currently has a consensus rating of “Hold” and a consensus target price of $22.26.

NYSE CLB opened at $20.19 on Friday. Core Laboratories has a one year low of $6.68 and a one year high of $48.40. The stock has a 50-day moving average of $16.09 and a 200 day moving average of $19.63. The company has a market capitalization of $898.35 million, a price-to-earnings ratio of -8.89, a PEG ratio of 5.48 and a beta of 3.15. The company has a debt-to-equity ratio of 2.64, a quick ratio of 0.74 and a current ratio of 0.99.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, October 21st. The oil and gas company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. Core Laboratories had a positive return on equity of 45.39% and a negative net margin of 19.02%. The company had revenue of $105.38 million during the quarter, compared to the consensus estimate of $109.33 million. During the same period last year, the company earned $0.50 EPS. Core Laboratories’s revenue for the quarter was down 39.2% on a year-over-year basis. On average, equities analysts predict that Core Laboratories will post 0.79 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, November 17th. Shareholders of record on Monday, October 26th were given a $0.01 dividend. The ex-dividend date of this dividend was Friday, October 23rd. This represents a $0.04 annualized dividend and a yield of 0.20%. Core Laboratories’s payout ratio is 2.23%.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Read More: Dead Cat Bounce

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.